The Management of stroke page has been updated with some information about andexanet for the treatment of ICH in patients taking DOACs – there is insufficient evidence of benefit to recommend it at present.
Future trials will need to be better designed than this one.
Connolly, S. J., Sharma, M., Cohen, A. T. et al., (2024). Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage. N Engl J Med, 390(19), 1745-1755. https://doi.org/10.1056/NEJMoa2313040